

Association of viral variant and vaccination status with the occurrence of symptoms compatible with post-acute sequelae after primary SARS-CoV-2 infection

Christian R. Kahlert^{1,2} MD, Carol Strahm¹ MD, Sabine Güsewell¹ PhD, Alexia Cusini³ MD, Angela Brucher⁴ MD, Stephan Goppel⁵ MD, J. Carsten Möller⁶ MD, Manuela Ortner⁷, Markus Ruetti⁸ MD, Reto Stocker⁹ MD, Danielle Vuichard-Gysin^{10,11} MD MSc, Ulrike Besold¹² MD, Allison McGeer¹³ MD MSc, Lorenz Risch^{14,15,16} MD PhD, Andrée Friedl¹⁷ MD, Matthias Schlegel¹ MD, Pietro Vernazza¹ MD, Stefan P. Kuster^{1*} MD MSc, Philipp Kohler^{1*} MD MSc, SURPRISE Study Group

Author affiliations:

¹ Cantonal Hospital St Gallen, Division of Infectious Diseases and Hospital Epidemiology, St Gallen, Switzerland

² Children's Hospital of Eastern Switzerland, Department of Infectious Diseases and Hospital Epidemiology, St. Gallen, Switzerland

³ Cantonal Hospital of Grisons, Division of Infectious Diseases, Chur, Switzerland

⁴ Psychiatry Services of the Canton of St. Gallen (South), Switzerland

⁵ Psychiatry Services of the Canton of St. Gallen (North), Switzerland

⁶ Center for Neurological Rehabilitation, Zihlschlacht, Switzerland

⁷ Rheintal Werdenberg Sarganserland Hospital Group, Grabs, Switzerland

⁸ Fuerstenland Toggenburg Hospital Group, Wil, Switzerland

⁹ Hirslanden Clinic, Zurich, Switzerland

¹⁰ Thurgau Hospital Group, Division of Infectious Diseases and Hospital Epidemiology, Muensterlingen, Switzerland

¹¹ Swiss National Centre for Infection Prevention (Swissnoso), Berne, Switzerland

¹² Geriatric Clinic St. Gallen, St. Gallen, Switzerland

¹³ Sinai Health System, Toronto, Canada

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

¹⁴ Labormedizinisches Zentrum Dr Risch Ostschweiz AG, Buchs, Switzerland

¹⁵ Private Universität im Fürstentum Liechtenstein, Triesen, Liechtenstein

¹⁶ Center of Laboratory Medicine, University Institute of Clinical Chemistry, University of Bern, Inselspital, Bern, Switzerland

¹⁷ Cantonal Hospital Baden, Division of Infectious Diseases and Hospital Epidemiology, Baden, Switzerland

Keywords: SARS-CoV-2, health care workers, viral variants, omicron, post-acute, post-covid condition

Corresponding author

Philipp Kohler

Cantonal Hospital St. Gallen, Division of Infectious Diseases and Hospital Epidemiology

Rorschacherstrasse 95

9007 St. Gallen, Switzerland

E-Mail: philipp.kohler@kssg.ch, Phone: +41 71 494 1148

1 **ABSTRACT**

2 **Importance:** Disentangling the effects of different SARS-CoV-2 variants and of vaccination on
3 the occurrence of post-acute sequelae of SARS-CoV-2 (PASC) is crucial to estimate and
4 potentially reduce the future burden of PASC.

5
6 **Objective:** To determine the association of primary SARS-CoV-2 infection on the frequency of
7 PASC symptoms by viral variant and vaccination status.

8
9 **Design:** Cross-sectional questionnaire and SARS-CoV-2 serology (May/June 2022) performed
10 within a prospective healthcare worker cohort (SURPRISE study).

11
12 **Setting:** Multicenter study in nine healthcare networks from North-Eastern Switzerland.

13
14 **Participants:** Volunteer sample of healthcare workers (HCW) from participating institutions. Of
15 approximately 20'000 eligible participants, 3'870 registered for the cohort and 2'912 were
16 included in this analysis.

17
18 **Exposures:** SARS-CoV-2 infection documented by positive nasopharyngeal swab (>4 weeks
19 ago), stratified by viral variant and vaccination status at time of infection, compared to absence
20 of documented infection (no positive swab, negative serology).

21
22 **Main Outcome:** Sum score of eighteen self-reported PASC symptoms.

23
24 **Results:** Among 2'912 participants (median age 44 years, 81.3% female), SARS-CoV-2
25 infection was reported by 1'685 (55.9%) participants, thereof 315 (18.7%) during Wild-type, 288
26 (17.1%) during Alpha/Delta, and 1'082 (64.2%) during Omicron circulation. Mean symptom
27 number in previously infected participants significantly exceeded that of uninfected controls
28 (0.39), but decreased with recency of the viral variant: 1.12 ($p<0.001$) for Wild-type (median

29 time since infection 18.5 months), 0.67 ($p < 0.001$) for Alpha/Delta (6.6 months), and 0.52
30 ($p = 0.005$) for Omicron BA.1 (3.1 months) infected participants. After Omicron BA.1 infection, the
31 mean symptom score was 0.49 ($p = 0.30$) for those with ≥ 3 prior vaccinations and 0.71 ($p = 0.028$)
32 with 1-2 previous vaccinations compared to 0.36 for unvaccinated individuals. Adjusting for
33 confounders, Wild-type (adjusted risk ratio [aRR] 2.81, 95% confidence interval [CI] 2.08-3.83)
34 and Alpha/Delta infection (aRR 1.93, 95% CI 1.10-3.46) showed significant associations with
35 the outcome, whereas Omicron BA.1 infection (aRR 1.29, 95% CI 0.69–2.43) and vaccination
36 before infection (aRR 1.27, 95% CI 0.82–1.94) did not.

37

38 **Conclusions and Relevance:** Previous infection with pre-Omicron variants was the strongest
39 risk factor for reporting PASC symptoms in this HCW cohort. A definite influence of prior
40 vaccination on the prevention of PASC after Omicron BA.1 infection was not measurable.

41

42 INTRODUCTION

43 Early in the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic,
44 it has become apparent that not all patients fully recover from Coronavirus Disease 2019
45 (COVID-19), but have persistent physical and mental health symptoms^{1,2}. As SARS-CoV-2
46 continues to evolve and its variants spread across the globe, post-acute sequelae after SARS-
47 CoV-2 (PASC) or Long COVID represents a significant challenge to healthcare systems³. The
48 estimates on the frequency of Long COVID vary greatly, depending on definitions used and time
49 elapsed since infection^{4,5}. The currently most common SARS-CoV-2 variant, Omicron, spreads
50 even more efficiently but seems less pathogenic in acute disease, at least in a population with
51 robust immunity⁶. As severity of acute infection has directly been associated with the risk of
52 developing PASC^{7,8}, this condition might be less common after Omicron infection compared to
53 previous variants. Indeed, previous data show that compared to the Delta variant, after COVID-
54 19 with Omicron, the risk for PASC is reduced by around 50%⁹. However, in this study,
55 comparison with Alpha and the Wild-type was not possible; also, the study lacked a control
56 group, which is crucial to correctly attribute these often non-specific symptoms to COVID-19¹⁰.
57 Decreasing prevalence of PASC over time has also been reported from an Italian healthcare
58 worker (HCW) cohort. In addition, the authors suggested that PASC develops less frequently in
59 individuals who are vaccinated against SARS-CoV-2 before being infected¹¹. Again, this study
60 did not include a control group and infections occurring in the Delta and Omicron period were
61 not evaluated separately.

62 In this study, we aimed to compare symptoms compatible with PASC between HCW after
63 infection with different SARS-CoV-2 variants and uninfected seronegative controls. Also, we
64 assessed the impact of mRNA COVID-19 vaccine on symptoms compatible with PASC.

65

66 **METHODS**

67 *Setting and participants*

68 The study was approved by the ethics committee of Eastern Switzerland. Written informed
69 consent was obtained from participants. The observational multicenter study included volunteer
70 HCW from eight healthcare networks in Northern/Eastern Switzerland¹². The study population
71 consisted mostly of participants from a previous HCW cohort, which had been launched in
72 July/August 2020. In addition, new participants were recruited for the current study (**Figure S1**).

73

74 *Study procedures*

75 Participants from the original cohort were prospectively followed between July/August 2020 and
76 May/June 2022 with electronic questionnaires capturing SARS-CoV-2 positive swabs and
77 vaccinations; also, repetitive SARS-CoV-2 serologies were performed (**Figure S2**)¹³.

78 In May/June 2022, the cross-sectional study was performed including SARS-CoV-2 serology
79 and an electronic questionnaire, asking about personal characteristics and risk factors, such as
80 comorbidities, medications, household members, work type, exposure to COVID-19 patients,
81 and the presence of PASC symptoms. Participants also reported dates of previous SARS-CoV-
82 2-positive nasopharyngeal swabs and vaccinations. Participants with multiple positive swabs
83 and those with a first positive swab within 4 weeks or a vaccination within 1 week prior to the
84 questionnaire were excluded.

85

86 *SARS-CoV-2 diagnostics*

87 Participants were asked to get tested for SARS-CoV-2 in case of compatible symptoms,
88 according to national recommendations. Depending on the participating institution, SARS-CoV-
89 2 was detected by rapid antigen test or polymerase chain reaction. Self-reported
90 nasopharyngeal swabs results were validated as previously described¹³. In May/June 2022,
91 participants were serologically screened for anti-spike (anti-S) and anti-nucleocapsid (anti-N)
92 antibodies, to identify pauci-/asymptomatically infected individuals¹². The Roche Elecsys (Roche
93 Diagnostics, Rotkreuz, Switzerland) electro-chemiluminescence immunoassay was used¹⁴.

94

95 *Definition of viral variant and vaccination status*

96 The viral variant infecting a participant was inferred from the time of first positive swab
97 according to sequencing data from Northeastern Switzerland¹⁵: Wild-type infections (February
98 2020 to January 2021); Alpha variant (February to June 2021); Delta variant (July to December
99 2021); Omicron variant (B.1.1.529.1; BA.1) (January to June 2022) (**Figure S2**). Infections
100 during the Alpha period were merged with those during the Delta period due to the small
101 number of Alpha infections. Participants without any previous positive SARS-CoV-2 swab and
102 with negative anti-N in May/June 2022 were considered as uninfected controls. Those without
103 positive SARS-CoV-2 swab but positive anti-N were excluded from further analyses.

104 Vaccination status was assessed based on self-reported participant data. Over 99% of
105 vaccinated participants indicated receipt of either the mRNA-1273 or the BNT162b2 vaccine.

106

107 *Outcomes*

108 Participants were given a list of symptoms compatible with PASC and were asked to check
109 those present at time of the questionnaire for more than 7 days but not before the pandemic.
110 Symptoms included loss of smell/taste, shortness of breath, chest pain, hair loss, brain fog,
111 tiredness/weakness, skin rash, muscle/limb pain, joint point, headache, nausea/anorexia,
112 dizziness, stomachache, diarrhea, burnout/exhaustion, fever >38° Celsius or feverish feeling,
113 chills, and cough. The main outcome was the total number of these 18 symptoms; individual
114 symptoms were also analyzed.

115 As additional outcomes, participants answered a 9-item fatigue score (Fatigue Severity Scale,
116 FSS)¹⁶, reported their self-rated health (SRH) on a 5-point scale (from “poor” to “excellent”)¹⁷,
117 and indicated whether they think they would suffer from Long COVID (yes vs. no). For those
118 answering the latter question with yes, the severity of Long COVID was assessed using the
119 Post-COVID-19 Functional Status Scale (PCFS), a 5-point scale from “no restrictions in daily
120 live” to “severe restrictions” (**Table S1**)^{18,19}.

121

122 *Statistical analysis*

123 We used descriptive statistics to compare baseline characteristics between those infected with
124 the Wild-type virus, the Alpha/Delta variant, the Omicron BA.1 variant, and uninfected controls.
125 For the main analysis, mean PASC symptom scores were compared between each of the
126 infected groups and controls, respectively, using univariable negative-binomial models. Mean
127 sum scores and 95% likelihood ratio confidence intervals (CI) were derived from models without
128 intercept. The significance of differences was evaluated using Wald tests on coefficients of
129 models with uninfected controls as intercept. The same analyses were performed separately by
130 vaccination status: unvaccinated, vaccinated after infection (controls with any vaccination date),
131 and vaccinated before infection with ≥ 1 vaccine dose (controls with any vaccination date).
132 Second, the frequency of individual symptoms was compared between each of the infected
133 groups and controls, respectively, using logistic regression. This analysis was performed
134 separately for those unvaccinated at time of infection (ie, never vaccinated individuals or
135 vaccination after infection) and those with ≥ 1 vaccine dose before infection. Controls were
136 uninfected individuals without and with any vaccination, respectively.
137 Third, we compared the mean symptom score between boosted (≥ 3 vaccinations at least 7 days
138 before infection) and non-boosted (1-2 vaccinations) compared to unvaccinated (but also
139 infected) participants using negative-binomial models. This analysis was restricted to
140 participants infected in the Delta (without the Alpha group) and Omicron period, because
141 booster vaccination was not available before.

142

143 *Multivariable analysis*

144 To assess the independent impact of viral variant and vaccination status on symptom number,
145 we used a multivariable negative-binomial regression model. Variables previously found to be
146 associated with the occurrence of Long COVID were included in the model (**Table S1**)^{7,20}. Rate
147 ratios (RR) derived from model coefficients and corresponding 95% CI are shown as forest
148 plots; P-values were obtained from Wald tests.

149

150 *Sensitivity analysis*

151 To minimize the risk of incorrect group assignment due to undetected earlier SARS-CoV-2
152 infection, we re-ran the main analysis and the multivariable analysis including only individuals
153 with previous serology data available and excluding those with any positive anti-N before the
154 first positive SARS-CoV-2 swab or before the survey (for controls) (**Figure S1**).

155

156 *Analysis of additional outcomes*

157 Additional outcomes were analyzed between each of the infected group and controls. For this
158 purpose, we used a negative-binomial model (FSS), logistic regression (self-classification of
159 having Long COVID), and proportional-odds logistic regression (distribution of SRH ratings and
160 PCFS). These analyses were not stratified by vaccination status. R statistical software Version
161 4.0.2 was used for statistical analysis; two-sided p-values of $<.05$ were considered significant.
162 This report follows the STROBE reporting guideline for observational studies²¹.

163

164 RESULTS

165 *Study population and SARS-CoV-2 infections*

166 Of approximately 19'600 eligible study participants, 3'870 answered the questionnaire in
167 May/June 2022 and 2'912 were included in the analysis (**Figure S1**). Median age was 44 years
168 and 81.3% were women. SARS-CoV-2 infection was reported by 1'685 (57.9%) participants,
169 thereof 315 (18.7%) during the Wild-type, 288 (17.1%) during the Alpha/Delta, and 1'082
170 (64.2%) during the Omicron period. Median time since infection was 18.3 months (interquartile
171 range [IQR] 17.5-19.2) for Wild-type, 6.5 (IQR 6.0-9.0) for Alpha/Delta, and 3.1 (IQR 2.6-4.0) for
172 Omicron BA.1 infections. The group of uninfected controls consisted of 1'227 individuals. Of the
173 2'912 individuals, 2'570 reported baseline characteristics (**Table 1**).

174

175 *PASC symptoms and viral variant*

176 The 2'912 participants reported a mean of 0.55 symptoms (including those without symptoms).
177 Mean symptom number in the three groups of previously infected participants significantly
178 exceeded that of uninfected controls (0.39), but decreased with recency of the viral variant: 1.12
179 ($p < 0.001$) for Wild-type, 0.67 ($p < 0.001$) for Alpha/Delta, and 0.52 ($p = 0.005$) for Omicron BA.1
180 infected participants (**Figure 1a**). Similar decreasing trends across viral variants were observed
181 for unvaccinated participants (**Figure 1b**), for those with vaccination before or after infection
182 (**Figure 1c**), and also in the sensitivity analysis, although sample size was small in individual
183 subgroups (**Figure S3**).

184 At least one symptom was reported by 695 (23.9%) participants, and this share was significantly
185 raised after infection: 38.7% for Wild-type infected participants ($p < 0.001$), 31.6% for Alpha/Delta
186 ($p = 0.001$), 23.8% for Omicron BA.1 ($p = 0.001$), compared to 18.3% for uninfected individuals.

187 The most commonly reported symptoms overall were tiredness/weakness with a frequency of
188 14.7% in infected and 9.4% in uninfected participants. Symptoms consistently associated with
189 SARS-CoV-2 infection across all variants were loss of smell/taste and hair loss for unvaccinated
190 (**Figure S4**), and loss of smell/taste and brain fog for vaccinated participants (**Figure S5**).

191

192 *PASC symptoms and vaccination status*

193 Among participants infected during the Delta period, vaccinated individuals (+/- booster)
194 reported on average fewer symptoms than unvaccinated participants; however, the differences
195 were not statistically significant. After Omicron BA.1 infection, the mean reported symptom
196 number was 0.49 (p=0.30) for those with ≥ 3 prior vaccinations and 0.71 (p=0.028) for those with
197 1-2 previous vaccinations compared to 0.36 for unvaccinated individuals (**Figure 2**).

198

199 *Multivariable analysis*

200 In multivariable analysis, infection with the Wild-type virus (adjusted rate ratio [aRR] 2.81, 95%
201 CI 2.08–3.83) and with the Alpha/Delta variant (aRR 1.93, 95% CI 1.10–3.46) were positively
202 associated with the number of symptoms reported, whereas infection during the Omicron period
203 (aRR 1.29, 95% CI 0.69–2.43) and vaccination before infection (aRR 1.27, 95% CI 0.82–1.94)
204 were not. Other variables associated with the outcome were body mass index (BMI) $>30\text{m/kg}^2$
205 (aRR 1.43, 95% CI 1.08–1.92), having a pre-existing comorbidity (RR 1.35, 95% CI 1.11–1.65),
206 being on any medication (aRR 1.49, 95% CI 1.20–1.86) and cumulative COVID-19 patient
207 contact (aRR 1.11, 95% CI 1.01–1.21) (**Figure 3, Table S2**). Effect sizes for viral variants
208 increased slightly in sensitivity analysis, whereas other co-variables, except being on any
209 medication, were no longer associated with the outcome (**Figure S6**).

210

211 *Additional outcomes*

212 Both the FSS and the SRH were highest or lowest, respectively, for those after Wild-type
213 infection, while no difference was observed between those with Alpha/Delta or Omicron BA.1
214 infection and controls (**Table 2**). The percentage of participants who considered themselves
215 suffering from Long COVID was substantially higher after Wild-type (17.1%, p<0.001),
216 Alpha/Delta (10.4%, p<0.001), and Omicron BA.1 infection (4.8%, p<0.001) compared to
217 controls (0.9%). For those suffering from Long COVID, functional impairment in daily live as per
218 the PCFS score was similar between groups.

219

220 DISCUSSION

221 Within a well-defined HCW population, we show that the most decisive risk factor for reporting
222 symptoms compatible with PASC is the viral variant causing the primary infection. Participants
223 after Wild-type SARS-CoV-2 and Alpha/Delta infections reported the highest numbers even 18
224 and 6 months after infection, respectively. In contrast, those at 3 months after Omicron BA.1
225 infection are only minimally affected compared to uninfected controls. SARS-CoV-2 vaccination
226 including receipt of booster vaccine before Omicron BA.1 infection was not associated with less
227 PASC symptoms.

228 The viral variant was the most important risk factor associated with the presence of PASC
229 symptoms, even after adjusting for co-variables typically associated with Long COVID, such as
230 age, sex, BMI, and vaccination status. Individuals after Wild-type reported significantly more
231 PASC symptoms, had a higher fatigue score and a lower SRH than uninfected controls. These
232 findings are particularly worrying considering that Wild-type infections occurred a median of 18
233 months before this survey. Few studies have reported such a long duration of PASC.
234 Persistence of symptoms for 12 months have been reported by several others, both in
235 hospitalized and non-hospitalized populations²²⁻²⁴. One study demonstrated the persistence of
236 memory problems at 18 months after mild SARS-CoV-2 infection and another showed that 38%
237 of infected patients still reported symptoms at 23 months after infection^{25,26}. In addition, some
238 authors have suggested that loss of smell/taste, which was one of the symptoms showing a
239 clear association with PASC in our study, might potentially be a permanent sequela after
240 COVID-19²⁷. Further research aiming at mitigating the PASC burden in those infected early on
241 in the pandemic is urgently needed.

242 The frequency of Long COVID after infection with the Omicron variant has been reported to be
243 5% at ≥ 4 weeks after infection, which is about half compared to the Delta variant⁹. Comparing
244 people infected with Omicron vs. previous variants, 5 vs. 55% reported ≥ 1 PASC symptom in
245 another study²⁸. However, both studies have not included a non-infected control group, which
246 allows to better interpret the significance of these findings. In our study, participants after
247 Omicron BA.1 infection still reported more symptoms than uninfected controls. However, we

248 found that many symptoms typically associated with PASC, such as fatigue, exhaustion or
249 muscle/limb pain,¹ were only slightly or not at all more common after Omicron BA.1 infection
250 compared to uninfected controls. On the other hand, the high prevalence of some of these
251 symptoms in uninfected individuals highlights the importance to also consider other causes,
252 besides COVID-19, underlying these symptoms. This particularly includes conditions such as
253 chronic fatigue syndrome/myalgic encephalomyelitis, which have been shown to be often
254 related to other viral infections²⁹⁻³¹. Importantly, in contrast to participants after Wild-type
255 infection, FSS and SRH were not any different between Omicron BA.1 infected and uninfected
256 controls.

257 Our data further suggest that vaccination with SARS-CoV-2 mRNA vaccines prior to Omicron
258 BA.1 infection does not lower the risk of PASC. This is in contrast to previous studies from the
259 pre-Omicron era, which showed a benefit of vaccination against PASC^{32,33}. In addition, an Italian
260 study found that vaccination before infection during the Delta/Omicron period was indeed
261 associated with decreased risk for long COVID¹¹. The discrepancy can be explained by the fact
262 that in this study, infections during the Delta and Omicron period were pooled; hence, the effect
263 of previous vaccination on Long COVID could have been mainly driven by Delta infections. In
264 line with this hypothesis, our data suggest that previous vaccination might have been protective
265 against PASC after Delta, although results were not statistically significant due to the small
266 number of cases. In contrast, previous vaccination was clearly not associated with a reduction
267 of PASC symptoms after Omicron BA.1 infection despite the large number of cases. Further
268 studies are needed to confirm our finding.

269 Important strengths of our study are the clearly defined infection and vaccine status of every
270 individual study participant as well as the relatively large share of hitherto unvaccinated
271 participants. This enabled us to adequately disentangle the effects of viral variant and of SARS-
272 CoV-2 vaccination on the occurrence of PASC symptoms, a task which is increasingly
273 becoming unrealizable due to high vaccination and infection rates, particularly in HCW³⁴. The
274 probably most important strength is the inclusion of a non-infected control group, which many
275 previous studies on Long COVID have lacked¹⁰. A Dutch study recently reported the frequency

276 of PASC symptoms in infected vs. non-infected individuals, and attributed these symptoms in
277 12.7% of cases to COVID-19. Yet, the study was performed before circulation of the Delta and
278 Omicron variants; furthermore, no SARS-CoV-2 serology was performed which would allow to
279 also capture asymptomatic infections³⁵. We relied on anti-N negativity to exclude previous
280 infection. We acknowledge that this definition may have missed a certain proportion of infected
281 individuals due to lack of seroconversion or waning antibody titers over time¹⁴. In a post-hoc
282 analysis, we found that 11.7% of those with negative anti-N reported indeed a positive swab. By
283 considering both criteria, anti-N negativity and lack of positive swab, we think that our approach
284 of defining an uninfected control group is reasonable. Furthermore, results of the sensitivity
285 analysis, which also considered previous serology results and excluded those with waning
286 immunity over time, largely confirmed our main findings.

287 Our study has further limitations. First, definition of viral variants was based on population data
288 and not on individual sequencing data. This might have led to misclassifications of viral variants
289 in any direction and therefore to an underestimation of the observed differences. Second, the
290 choice of our outcome definition can be debated. The large number of symptoms and the less
291 strict time criterion (symptoms had to be present at least for 7 days) compared to other studies
292 might have led to an overestimation of PASC prevalence. Third, we cannot exclude that vaccine
293 hesitancy could be associated with the way people perceive and/or report physical and mental
294 health symptoms, which would distort the comparability between vaccinated and unvaccinated
295 participants. Fourth, our data lack generalizability both in terms of study population as well as of
296 viral variants. We cannot exclude that Omicron BA.1 infections occurring in the elderly or more
297 comorbid populations, where acute infection might manifest itself more severely, might confer
298 an increased risk of PASC; also, our results are not necessarily applicable to newer Omicron
299 variants.

300 To conclude, these data suggest that in a HCW population of predominantly young, healthy
301 Caucasian females, individuals infected with the Wild-type, and less so with the Alpha/Delta
302 variants, still report symptoms compatible with PASC after a median of 18 and 6 months,
303 respectively, whereas the burden at 3 months after Omicron BA.1 infection is considerably

304 lower. Vaccination prior to Omicron BA.1 infection was not associated with less PASC
305 symptoms. Future research should primarily address the needs of individuals infected early on
306 in the pandemic, whereas in individuals suffering from symptoms compatible with PASC after
307 Omicron BA.1 infection, other aetiologies besides COVID-19 should be actively sought.
308

309 **Acknowledgments**

310 We also thank the participants of the SURPRISE study and the members of the study group (in
311 alphabetical order): Ulrike Besold, MD (Geriatric Clinic St. Gallen), Angela Brucher, MD
312 (Psychiatry Services South, St. Gallen), Alexia Cusini, MD (Cantonal Hospital Graubünden),
313 Thomas Egger (Cantonal Hospital St. Gallen), Andrée Friedl, MD (Cantonal Hospital Baden),
314 Stephan Goppel, MD (Psychiatry Services North, St. Gallen), Fabian Grässli, MSc (Cantonal
315 Hospital St. Gallen), Christian R. Kahlert, MD (Children's Hospital of Eastern Switzerland, St.
316 Gallen), Joelle Keller (Hirslanden Clinic Zurich), Simone Kessler (Cantonal Hospital St. Gallen),
317 Philipp Kohler, MD MSc (Cantonal Hospital St. Gallen), Stefan P. Kuster, MD MSc (Cantonal
318 Hospital St. Gallen), Onicio Leal, PhD (University of Zurich), Eva Lemmenmeier, MD (Cliebia
319 Littenheid), Allison McGeer, MD MSc (Mount Sinai Hospital, Toronto), Dorette Meier Kleeb, MD
320 (Cantonal Hospital Baden), J. Carsten Möller, MD (Clinic Zihlschlacht), Maja F. Müller
321 (Hirslanden Clinic Zurich), Vaxhid Musa (Cantonal Hospital St. Gallen), Manuela Ortner
322 (Rheintal Werdenberg Sarganserland Hospital Group, Grabs), Philip Rieder, PhD (Hirslanden
323 Clinic Zurich), Lorenz Risch, MD PhD (Laboratory Risch Buchs), Markus Ruetti, MD
324 (Fuerstenland Toggenburg Hospital Group Wil), Matthias Schlegel, MD (Cantonal Hospital St.
325 Gallen), Hans-Ruedi Schmid, PhD (Cantonal Hospital Baden), Reto Stocker, MD (Hirslanden
326 Clinic Zurich), Pietro Vernazza, MD (Cantonal Hospital St. Gallen), Matthias von Kietzell MD
327 (Clinic Stephanshorn St. Gallen), Danielle Vuichard-Gysin, MD MSc (Thurgau Hospital Group
328 Muensterlingen), and Benedikt Wiggli, MD (Cantonal Hospital Baden).

329
330 This work was supported by the Swiss National Sciences Foundation (grant number
331 31CA30_196544; grant number PZ00P3_179919 to PK), the Federal Office of Public Health
332 (grant number 20.008218/421-28/1), the Health Department of the Canton of St. Gallen, and the
333 research fund of the Cantonal Hospital of St. Gallen. Funding institutions did not have any role
334 in design and conduct of the study; collection, management, analysis, and interpretation of the
335 data; preparation, review, or approval of the manuscript; and decision to submit the manuscript
336 for publication.

337 The authors have no other conflicts of interest to declare.

338 REFERENCES

- 339 1. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med*. 2021;27(4):601-
340 615. doi:10.1038/s41591-021-01283-z
- 341 2. Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study. *BMJ*.
342 2022;376:e068993. doi:10.1136/bmj-2021-068993
- 343 3. Phillips S, Williams MA. Confronting Our Next National Health Disaster — Long-Haul Covid. *N Engl J*
344 *Med*. 2021;385(7):577-579. doi:10.1056/NEJMp2109285
- 345 4. Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent
346 Symptoms Among Patients With COVID-19: A Systematic Review. *JAMA Netw Open*.
347 2021;4(5):e2111417. doi:10.1001/jamanetworkopen.2021.11417
- 348 5. Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals
349 With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic
350 COVID-19 in 2020 and 2021. *JAMA*. Published online October 10, 2022.
351 doi:10.1001/jama.2022.18931
- 352 6. Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and
353 death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a
354 cohort study. *Lancet Lond Engl*. 2022;399(10332):1303-1312. doi:10.1016/S0140-6736(22)00462-7
- 355 7. Strahm C, Seneghini M, Güsewell S, et al. Symptoms compatible with long-COVID in healthcare
356 workers with and without SARS-CoV-2 infection - results of a prospective multicenter cohort. *Clin*
357 *Infect Dis Off Publ Infect Dis Soc Am*. Published online January 28, 2022:ciac054.
358 doi:10.1093/cid/ciac054
- 359 8. Bahmer T, Borzikowsky C, Lieb W, et al. Severity, predictors and clinical correlates of post-COVID
360 syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
361 *EClinicalMedicine*. 2022;51:101549. doi:10.1016/j.eclinm.2022.101549
- 362 9. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta
363 versus omicron variants of SARS-CoV-2. *The Lancet*. 2022;399(10343):2263-2264.
364 doi:10.1016/S0140-6736(22)00941-2
- 365 10. Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for
366 characterizing long COVID. *Nat Med*. 2021;27(7):1129-1130. doi:10.1038/s41591-021-01402-w
- 367 11. Azzolini E, Levi R, Sarti R, et al. Association Between BNT162b2 Vaccination and Long COVID After
368 Infections Not Requiring Hospitalization in Health Care Workers. *JAMA*. 2022;328(7):676-678.
369 doi:10.1001/jama.2022.11691
- 370 12. Kahlert CR, Persi R, Güsewell S, et al. Non-occupational and occupational factors associated with
371 specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. *Clin*
372 *Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*. 2021;27(9):1336-1344.
373 doi:10.1016/j.cmi.2021.05.014
- 374 13. Kohler P, Güsewell S, Seneghini M, et al. Impact of baseline SARS-CoV-2 antibody status on
375 syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort
376 study. *BMC Med*. 2021;19(1):270. doi:10.1186/s12916-021-02144-9
- 377 14. Baron RC, Risch L, Weber M, et al. Frequency of serological non-responders and false-negative RT-
378 PCR results in SARS-CoV-2 testing: a population-based study. *Clin Chem Lab Med*. Published online
379 August 31, 2020. doi:10.1515/cclm-2020-0978
- 380 15. Federal Office of Public Health. Virus variants overview. Last accessed April 1st 2021.
381 <https://www.covid19.admin.ch/en/epidemiologic/virus-variants>

- 382 16. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: Application to
383 Patients With Multiple Sclerosis and Systemic Lupus Erythematosus. *Arch Neurol.* 1989;46(10):1121-
384 1123. doi:10.1001/archneur.1989.00520460115022
- 385 17. Idler EL, Benyamini Y. Self-rated health and mortality: a review of twenty-seven community studies. *J*
386 *Health Soc Behav.* 1997;38(1):21-37.
- 387 18. Klok FA, Boon GJAM, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure
388 functional status over time after COVID-19. *Eur Respir J.* 2020;56(1):2001494.
389 doi:10.1183/13993003.01494-2020
- 390 19. Machado FVC, Meys R, Delbressine JM, et al. Construct validity of the Post-COVID-19 Functional
391 Status Scale in adult subjects with COVID-19. *Health Qual Life Outcomes.* 2021;19(1):40.
392 doi:10.1186/s12955-021-01691-2
- 393 20. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med.*
394 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
- 395 21. STROBE, Strengthening the reporting of observational studies in epidemiology. [https://www.strobe-](https://www.strobe-statement.org)
396 [statement.org](https://www.strobe-statement.org)
- 397 22. Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post-COVID-19
398 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort
399 study in Moscow (StopCOVID). *BMC Med.* 2022;20(1):244. doi:10.1186/s12916-022-02448-4
- 400 23. Seeßle J, Waterboer T, Hippchen T, et al. Persistent Symptoms in Adult Patients 1 Year After
401 Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. *Clin Infect Dis Off Publ Infect*
402 *Dis Soc Am.* 2022;74(7):1191-1198. doi:10.1093/cid/ciab611
- 403 24. Haddad A, Janda A, Renk H, et al. Long COVID symptoms in exposed and infected children,
404 adolescents and their parents one year after SARS-CoV-2 infection: A prospective observational
405 cohort study. *EBioMedicine.* 2022;84:104245. doi:10.1016/j.ebiom.2022.104245
- 406 25. Fjelltveit EB, Blomberg B, Kuwelker K, et al. Symptom Burden and Immune Dynamics 6 to 18 Months
407 Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-
408 control Study. *Clin Infect Dis.* Published online August 12, 2022:ciac655. doi:10.1093/cid/ciac655
- 409 26. Helmsdal G, Hanusson KD, Kristiansen MF, et al. Long COVID in the Long Run—23-Month Follow-
410 up Study of Persistent Symptoms. *Open Forum Infect Dis.* 2022;9(7):ofac270.
411 doi:10.1093/ofid/ofac270
- 412 27. Mendes Paranhos AC, Nazareth Dias ÁR, Machado da Silva LC, et al. Sociodemographic
413 Characteristics and Comorbidities of Patients With Long COVID and Persistent Olfactory
414 Dysfunction. *JAMA Netw Open.* 2022;5(9):e2230637. doi:10.1001/jamanetworkopen.2022.30637
- 415 28. Morioka S, Tsuzuki S, Suzuki M, et al. Post COVID-19 condition of the Omicron variant of SARS-
416 CoV-2. *J Infect Chemother Off J Jpn Soc Chemother.* 2022;28(11):1546-1551.
417 doi:10.1016/j.jiac.2022.08.007
- 418 29. Magnus P, Gunnes N, Tveito K, et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)
419 is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza
420 vaccine. *Vaccine.* 2015;33(46):6173-6177. doi:10.1016/j.vaccine.2015.10.018
- 421 30. Petersen I, Thomas JM, Hamilton WT, White PD. Risk and predictors of fatigue after infectious
422 mononucleosis in a large primary-care cohort. *QJM Mon J Assoc Physicians.* 2006;99(1):49-55.
423 doi:10.1093/qjmed/hci149
- 424 31. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nat Med.*
425 2022;28(5):911-923. doi:10.1038/s41591-022-01810-6

- 426 32. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat Med.*
427 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0
- 428 33. Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-
429 CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based,
430 nested, case-control study. *Lancet Infect Dis.* 2022;22(1):43-55. doi:10.1016/S1473-3099(21)00460-
431 6
- 432 34. Adriaenssens N, Scholtes B, Bruyndonckx R, et al. Prevalence, incidence and longevity of antibodies
433 against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study
434 with 12 months of follow-up. *BMJ Open.* 2022;12(9):e065897. doi:10.1136/bmjopen-2022-065897
- 435 35. Ballering AV, Zon SKR van, Hartman TC olde, Rosmalen JGM. Persistence of somatic symptoms
436 after COVID-19 in the Netherlands: an observational cohort study. *The Lancet.*
437 2022;400(10350):452-461. doi:10.1016/S0140-6736(22)01214-4
- 438

439 **TABLES**

440 Table 1. Characteristics of 2'570 participants answering the study questionnaire by time of first
441 positive SARS-CoV-2 swab.

Baseline characteristics	Wild-type infection <i>n</i> = 283	Alpha/Delta infection <i>n</i> = 268	Omicron infection <i>n</i> = 963	No infection <i>n</i> = 1056	<i>p</i> -value ^b
Age (years, median and IQR)	44 (33-54)	42 (32-49)	42 (34-52)	48 (37-56)	<0.001
Sex (male vs. female)	54 (19.1%)	47 (17.5%)	173 (18.0%)	206 (19.5%)	0.787
BMI (>30 vs. ≤30 kg/m ²)	40 (14.1%)	23 (8.6%)	97 (10.1%)	134 (12.7%)	0.055
Ethnicity (Caucasian)	275 (97.2%)	259 (96.6%)	946 (98.2%)	1024 (97.0%)	0.442
Child ≤ 6 years in household	36 (12.7%)	36 (13.4%)	150 (15.6%)	91 (8.6%)	<0.001
Any comorbidity	143 (50.5%)	116 (43.3%)	467 (48.5%)	514 (48.7%)	0.343
Pollen allergy	86 (30.4%)	77 (28.7%)	322 (33.4%)	331 (31.3%)	0.438
Other comorbidities	86 (30.4%)	58 (21.6%)	254 (26.4%)	299 (28.3%)	0.085
Any medication	97 (34.3%)	66 (24.6%)	271 (28.1%)	335 (31.7%)	0.026
Active smoking	41 (14.5%)	44 (16.4%)	154 (16.0%)	200 (18.9%)	0.186
Alcohol (>1 drink per week)	113 (39.9%)	103 (38.4%)	424 (44.0%)	419 (39.7%)	0.089
Profession					<0.001
Nurse	175 (61.8%)	149 (55.6%)	459 (47.7%)	476 (45.1%)	
Physician	27 (9.5%)	23 (8.6%)	127 (13.2%)	163 (15.4%)	
Other	81 (28.6%)	96 (35.8%)	377 (39.1%)	417 (39.5%)	
Cumulative contact duration to COVID-19 patients (minutes, median and IQR)	400 (30-2250)	285 (1-1200)	150 (1-1000)	130 (1-750)	<0.001
Intensive care	52 (18.4%)	32 (11.9%)	133 (13.8%)	140 (13.3%)	0.113
Full-time work (>0.8 FTE)	147 (51.9%)	128 (47.8%)	475 (49.3%)	561 (53.1%)	0.239
Vaccination ^a					<0.001
before infection	0 (0.0%)	165 (61.6%)	876 (91.0%)	0 (0.0%)	
after or without infection	255 (90.1%)	35 (13.1%)	3 (0.3%)	1022 (96.8%)	
no vaccination	28 (9.9%)	68 (25.4%)	84 (8.7%)	34 (3.2%)	

442 IQR, Interquartile Range; BMI, Body Mass Index; FTE, Full Time Equivalent

443 ^a Note that numbers are slightly lower than in Figure 1 because 342 individuals only reported data on infections and vaccinations, but no further data.

444 ^b Global test for the significance of group differences. Kruskal-Wallis test for numeric variables (age, cumulative patient contact duration) and Chi-squared test for categorical variables (all others).

446

447 Table 2. Results of additional outcomes by time of first infection (or no infection) among 2'912
448 participants.

449

	Wild-type infection <i>n</i> = 315	Alpha/Delta infection <i>n</i> = 288	Omicron infection <i>n</i> = 1082	No infection <i>n</i> = 1227
Fatigue severity score, FSS (mean) ^a	22.5**	20.4 ^{ns}	20.4 ^{ns}	20.5 ^{ref}
Self-reported health, SRH (mean) ^a	4.18*	4.36*	4.30 ^{ns}	4.30 ^{ref}
1 (Very bad)	0.6%	1.0%	0.5%	0.3%
2 (Bad)	0.3%	0.3%	0.7%	0.4%
3 (Average)	14.3%	7.6%	8.1%	8.0%
4 (Good)	49.5%	43.4%	49.5%	51.4%
5 (Very good)	35.2%	47.6%	41.1%	39.9%
Having long COVID (n [%]) ^a	54 (17.1%)***	30 (10.4%)***	52 (4.8%)***	11 (0.9%) ^{ref}
PCFS (mean) ^a	2.25 ^{ns}	2.14*	2.32 ^{ns}	2.73 ^{ref}
1 (No restrictions) ^b	14.8%	36.7%	17.3%	0%
2 (Negligible restrictions) ^b	53.7%	33.3%	44.2%	45.5%
3 (Restrictions, able to fulfill daily activities) ^b	24.1%	13.3%	26.9%	36.4%
4 (Restrictions, not able to fulfill daily activities) ^b	7.4%	16.7%	11.5 %	18.2%
5 (Severe restrictions) ^b	0%	0%	0%	0%

450 ^a Asterisks indicate statistically significant differences in outcome distribution between each infected group and uninfected controls,
451 as given by p-values from Wald tests on the coefficients of a negative binomial model for FSS, proportional-odds logistic regression
452 for SRH and PCFS, and ordinary logistic regression for having long COVID (***, *p* < 0.001; **, *p* < 0.01; *, *p* < 0.05; ^{ns}, *p* ≥ 0.05, ^{ref},
453 reference group).

454 ^b Percentages refer to the number of participants with self-reported long COVID
455 PCFS, Post-COVID-19 Functional Status Scale (assessed only by those with self-reported long COVID)

456

457 **FIGURES**

458 Figure 1. Cross-sectional analysis of May/June 2022. Means and 95% confidence intervals of
459 post-acute sequelae of SARS-CoV-2 symptom score by viral variant and vaccination status.

460 Asterisks above bars indicate statistical significance in reference to uninfected participants with
461 same vaccination status, respectively, as obtained through Wald tests on coefficients of
462 negative binomial models with uninfected participants as reference group (***, $p < 0.001$; **, $p <$
463 0.01 ; *, $p < 0.05$; ^{ns}, $p \geq 0.05$). N at the bottom of the bars designate number of participants.

464 Note: there were no vaccinations before Wild-type infection and only three individuals
465 vaccinated after Omicron BA.1 infection (not shown in panel C).

466

467

468 Figure 2. Means and 95% confidence intervals of post-acute sequelae of SARS-CoV-2
469 symptom score in relation to number of vaccine doses received before positive swab. Left:
470 Participants after infection in Delta period (1 July 1st to December 31th 2021). Right: Participants
471 after infection in Omicron BA.1 period (January 1st to June 30th 2022). Asterisks above bars
472 indicate statistical significance in reference to unvaccinated participants infected in the same
473 period, respectively, as obtained through Wald tests on coefficients of negative binomial models
474 with group "none" as reference (*, $p < 0.05$; ^{ns}, $p \geq 0.05$).


475
476
477
478
479
480
481
482

483 Figure 3. Results of multivariable negative binomial model regarding number of symptoms
484 compatible with post-acute sequelae of SARS-CoV-2. Predictors positively associated with
485 symptom number (i.e. 95% confidence interval for rate ratio entirely above 1) are highlighted in
486 red. For numeric values of point estimates and 95% confidence intervals see Table S3.


487
488

Number of symptoms

A All participants



B Unvaccinated participants



C Vaccinated participants

